-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, TOxLWHY98pSG8eiHDbE5aU+RJpfdBqV3XtFq2P1a+RR4s7mXaf/IUZ+rqQsNZihJ 57imZ6xsEyKAmsKeztzOTw== 0001209191-10-052012.txt : 20101028 0001209191-10-052012.hdr.sgml : 20101028 20101028180049 ACCESSION NUMBER: 0001209191-10-052012 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20101028 FILED AS OF DATE: 20101028 DATE AS OF CHANGE: 20101028 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BURRIS MICHELLE CENTRAL INDEX KEY: 0001229765 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33054 FILM NUMBER: 101149249 MAIL ADDRESS: STREET 1: 20235 S.E. STREET 2: 19TH STREET CITY: SAMMAMISH STATE: WA ZIP: 98075 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Trubion Pharmaceuticals, Inc CENTRAL INDEX KEY: 0001298521 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2401 4TH AVENUE STREET 2: SUITE 1050 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: 2068380500 MAIL ADDRESS: STREET 1: 2401 4TH AVENUE STREET 2: SUITE 1050 CITY: SEATTLE STATE: WA ZIP: 98121 4 1 doc4.xml FORM 4 SUBMISSION X0303 4 2010-10-28 1 0001298521 Trubion Pharmaceuticals, Inc TRBN 0001229765 BURRIS MICHELLE 20235 SE 19TH STREET SAMMAMISH WA 98075 0 1 0 0 Senior V.P. and C.O.O. Common Stock 0 D Employee Stock Option (right to buy) 6.52 2010-10-28 4 D 0 79732 0.00 D 2016-03-08 Common Stock 79732 0 D Employee Stock Option (right to buy) 8.98 2010-10-28 4 D 0 52000 0.00 D 2018-01-31 Common Stock 52000 0 D Employee Stock Option (right to buy) 1.33 2010-10-28 4 D 0 27500 0.00 D 2019-01-30 Common Stock 27500 0 D Employee Stock Option (right to buy) 1.33 2010-10-28 4 D 0 50000 0.00 D 2019-01-30 Common Stock 50000 0 D Employee Stock Option (right to buy) 3.82 2010-10-28 4 D 0 45000 0.00 D 2020-01-29 Common Stock 45000 0 D This option, which was 100% vested on February 6, 2010, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates, without any consideration being received. This option, which provided for vesting at the rate of 1/48 beginning on February 1, 2008, and 1/48th monthly thereafter, such that all of the shares would be fully vested as of January 1, 2012, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates, without any consideration being received. This option. which provided for vesting at the rate of 1/36th on August 27, 2009, and then 1/36th monthly thereafter, such that all of the shares would be fully vested as of July 27, 2012, was vested in its entirety and then cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $88,550, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 27,500 contingent value rights, which represents the right to receive possible additional future cash payments. This option, which provided for vesting at the rate of 1/48th on February 1, 2009, and then 1/48th monthly thereafter, such that all of the shares would be fully vested as of January 1, 2013, was vested in its entirety and then cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $161,000, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 50,000 contingent value rights, which represents the right to receive possible additional future cash payments. This option, which provided for vesting at the rate of 1/48th on February 1, 2010, and then 1/48th monthly thereafter, such that all of the shares would be fully vested as of January 1, 2014, was vested in its entirety and then cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $32,850, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 45,000 contingent value rights, which represents the right to receive possible additional future cash payments. /s/ Kathleen M. Deeley as attorney-in-fact for Michelle Burris 2010-10-28 -----END PRIVACY-ENHANCED MESSAGE-----